New GH-Releasing Peptides Designed from Ipamorelin Show High Potency
Researchers created a new series of modified ipamorelin derivatives using peptidomimetic design, achieving potent GH release with smaller, more drug-like molecules.
Quick Facts
What This Study Found
Sequential backbone modifications of ipamorelin produced smaller peptidomimetic compounds that retained potent GH secretagogue activity, advancing the goal of orally active GH-releasing peptides.
Key Numbers
How They Did This
Medicinal chemistry study involving systematic structural modification of ipamorelin, synthesis of peptidomimetic analogs, and in vitro/in vivo GH release assays to evaluate potency.
Why This Research Matters
Oral bioavailability is a major challenge for peptide therapeutics. This work shows that ipamorelin's core activity can be preserved in smaller, more drug-like molecules, bringing the goal of an oral GH secretagogue closer to reality.
The Bigger Picture
Ipamorelin is valued for its selective GH release without significant effects on cortisol or prolactin. Creating oral versions of ipamorelin-like molecules could make GH peptide therapy more accessible and convenient, moving beyond injection-only administration.
What This Study Doesn't Tell Us
Published in 1998 — oral bioavailability data may be preliminary. In vivo pharmacokinetics not fully characterized. Long-term safety of novel peptidomimetics unknown.
Questions This Raises
- ?Did any of these ipamorelin derivatives achieve meaningful oral bioavailability?
- ?Do the modified compounds retain ipamorelin's selectivity for GH over cortisol/prolactin?
- ?How do these compounds compare to MK-677 in terms of oral activity?
Trust & Context
- Key Stat:
- Potent GH release retained Smaller peptidomimetic ipamorelin derivatives maintained strong GH secretagogue activity with improved drug-like properties
- Evidence Grade:
- Medicinal chemistry study published in Journal of Medicinal Chemistry. Strong synthetic and pharmacological work, but clinical translation not demonstrated.
- Study Age:
- Published in 1998, this represents early peptidomimetic drug design efforts for GH secretagogues. The approach influenced subsequent oral GH secretagogue development.
- Original Title:
- A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
- Published In:
- Journal of medicinal chemistry, 41(19), 3699-704 (1998)
- Authors:
- Ankersen, M(4), Johansen, N L(3), Madsen, K(2), Hansen, B S, Raun, K, Nielsen, K K, Thogersen, H, Hansen, T K, Peschke, B, Lau, J, Lundt, B F, Andersen, P H
- Database ID:
- RPEP-00448
Evidence Hierarchy
Frequently Asked Questions
Why is making oral peptide drugs so difficult?
Peptides are naturally broken down by digestive enzymes and poorly absorbed through the gut lining. Making them orally available requires redesigning their structure to resist breakdown while keeping their biological activity.
How is ipamorelin different from other GH-releasing peptides?
Ipamorelin is notable for being highly selective — it stimulates GH release without significantly affecting cortisol or prolactin levels, making it one of the cleanest GH secretagogues in its class.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00448APA
Ankersen, M; Johansen, N L; Madsen, K; Hansen, B S; Raun, K; Nielsen, K K; Thogersen, H; Hansen, T K; Peschke, B; Lau, J; Lundt, B F; Andersen, P H. (1998). A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.. Journal of medicinal chemistry, 41(19), 3699-704.
MLA
Ankersen, M, et al. "A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.." Journal of medicinal chemistry, 1998.
RethinkPeptides
RethinkPeptides Research Database. "A new series of highly potent growth hormone-releasing pepti..." RPEP-00448. Retrieved from https://rethinkpeptides.com/research/ankersen-1998-a-new-series-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.